Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review

Akamine, Christine M.; Sahly, Hana M. El

doi:10.1016/j.trsl.2021.12.007

Cited by 4 publications

(5 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences in sociodemographic, clinical, ventilatory or pharmacological variables were observed between survivors and nonsurvivors. As previously demonstrated in this study population (8), no great differences are observed between those patients with BAS samples and all patients under IMV or patients under IMV without BAS samples. Concerning the pulmonary sequelae, the main characteristics of the study population are reflected in Table 3.…”

Section: Specific Proteomic Factors Quantified In Bronchial Aspirates...supporting

confidence: 81%

“…Patients admitted to the intensive care unit (ICU) show mortality rates exceeding 25-30% (5), particularly among those requiring invasive mechanical ventilation (IMV) (6). Despite the effectiveness of COVID-19 vaccines (7,8), ICU admission of patients with SARS-CoV-2-induced ARDS remains a challenge for health systems (9). The appearance of novel contagious SARS-CoV-2 strains should not be discarded (10).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

IntroductionBronchial aspirates (BAS) obtained during invasive mechanical ventilation (IMV) constitutes a useful tool for molecular phenotyping and decision making.AimTo identify the proteomic determinants associated with disease pathogenesis, all-cause mortality and respiratory sequelae in BAS samples from critically ill patients with SARS-CoV-2-induced ARDSMethodsMulticenter study including 74 critically ill patients with COVID-19 and non-COVID-19 ARDS. BAS were obtained by bronchoaspiration after IMV initiation. Three hundred sixty-four proteins were quantified using proximity extension assay (PEA) technology. Random forest models were used to assess predictor importance.ResultsAfter adjusting for confounding factors, CST5, NADK, SRPK2 and TGF-α were differentially detected in COVID-19 and non-COVID-19 patients. In random forest models for COVID-19, CST5, DPP7, NADK, KYAT1 and TYMP showed the highest variable importance. In COVID-19 patients, reduced levels of ENTPD2 and PTN were observed in nonsurvivors of ICU stay, even after adjustment. AGR2, NQO2, IL-1α, OSM and TRAIL showed the strongest associations with in-ICU mortality and were used to construct a protein-based prediction model. Kaplan-Meier curves revealed a clear separation in mortality risk between subgroups of PTN, ENTPD2 and the prediction model. Cox regression models supported these findings. In survivors, the levels of FCRL1, NTF4 and THOP1 in BAS samples obtained during the ICU stay correlated with lung function (i.e., DLCO levels) 3 months after hospital discharge. Similarly, Flt3L and THOP1 levels were correlated with radiological features (i.e., TSS). These proteins are expressed in immune and nonimmune lung cells. Poor host response to viral infectivity and an inappropriate reparative mechanism seem to be linked with the pathogenesis of the disease and fatal outcomes, respectively.ConclusionBAS proteomics identified novel factors associated with the pathology of SARS-CoV-2-induced ARDS and its adverse outcomes. BAS-based protein testing emerges as a novel tool for risk assessment in the ICU.

show abstract

Section: Specific Proteomic Factors Quantified In Bronchial Aspirates...supporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Safe and effective messenger RNA (mRNA) vaccines successfully aborted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic [171].…”

Section: Diabetes Mellitus and Mrna Vaccinationmentioning

confidence: 99%

SARS-CoV-2 Vaccines-Related Endocrine Disorders: An Updated Narrative Review

Ishay,

Oleinikov,

Shacham

2024

Preprint

View full text Add to dashboard Cite

The emergence of the COVID-19 pandemic has led to the rapid and worldwide devel-opment and investigation of multiple vaccines. While most side effects of these vaccines are mild and transient, potentially severe adverse events may occur and involve the endocrine system. This narrative review aims to explore the current knowledge on potential endocrine adverse effects following COVID-19 vaccination, with thyroid disorders being the most common. Data about pi-tuitary, adrenal, diabetes, and gonadal events will also be reviewed. This review also provides a comprehensive understanding of the pathogenesis of endocrine disorders associated with SARS-CoV-2 vaccines. A PubMed/MEDLINE, Embase database (Elsevier), and Google Scholar research were performed. Case reports case series, original studies, and reviews written in English and published online up to 31 August 2023 were selected and reviewed. Data on endocrine adverse events of SARS-CoV-2 vaccines is accumulating. However, their causal relationship with COVID-19 vaccines is not strong enough to make a definite conclusion, and further studies are needed to clarify the pathogenesis mechanisms of endocrine disorders linked to COVID-19 vac-cines.

show abstract

“…The genome of SARS-CoV-2 was made public on January 11, 2020, and the first clinical batch of the National Institute of Health (NIH) and Moderna's COVID-19 vaccine mRNA-1273 was completed on February 7, 2020 [15]. Reviews have detailed the preclinical development of COVID-19 mRNA vaccines [1 ▪ ,3 ▪ ]. On the basis of knowledge of the spike (S) protein gained from prior studies of SARS-CoV, human coronavirus HKU1, and Middle East respiratory syndrome coronavirus (MERS-CoV), two proline substitutions (L986P and V987P) were introduced in the central helix of the spike (S) protein sequence to stabilize the prefusion conformation and improve immunogenicity (2-SP design) [16,17].…”

Section: Mrna Vaccines Against Sars-cov-2mentioning

confidence: 99%

“…Although mRNA vaccine development evolved over decades [1 ▪ ], the successes of mRNA vaccines against severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) sparked a renaissance in mRNA vaccine development against multiple pathogens [2 ▪▪ ]. During the COVID-19 pandemic, mRNA vaccine platform advantages included rapid vaccine design and production [3 ▪ ], nimble adaptation to ever-changing SARS-CoV-2 variants [4–6], acceptable safety profiles [7,8], robust immunogenicity, and efficacy against severe coronavirus disease 2019 (COVID-19) and death [7–10]. The mRNA vaccine platform has challenges, such as cold storage requirements, increased reactogenicity compared with other vaccine platforms [11], and cost-effective and sustainable manufacturing [12].…”

Section: Introductionmentioning

confidence: 99%

mRNA vaccines against respiratory viruses

Whitaker

Sahly

Healy

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review The successes of the coronavirus disease 2019 (COVID-19) mRNA vaccines have accelerated the development of mRNA vaccines against other respiratory pathogens. The aim of this review is to highlight COVID-19 mRNA vaccine advances and provide an update on the progress of mRNA vaccine development against other respiratory pathogens. Recent findings The COVID-19 mRNA vaccines demonstrated effectiveness in preventing severe COVID-19 and death. H7N9 and H10N8 avian influenza mRNA vaccines have demonstrated safety and immunogenicity in phase 1 clinical trials. Numerous seasonal influenza mRNA vaccines are in phase 1–3 clinical trials. Respiratory syncytial virus (RSV) mRNA vaccines have progressed to phase 2–3 clinical trials in adults and a phase 1 clinical trial in children. A combined human metapneumovirus and parainfluenza-3 mRNA vaccines was found to be well tolerated and immunogenic in a phase 1 trial among adults and trials are being conducted among children. Clinical trials of mRNA vaccines combining antigens from multiple respiratory viruses are underway. Summary The development of mRNA vaccines against respiratory viruses has progressed rapidly in recent years. Promising vaccine candidates are moving through the clinical development pathway to test their efficacy in preventing disease against respiratory viral pathogens.

show abstract

Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review

Cited by 4 publications

References 134 publications

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

SARS-CoV-2 Vaccines-Related Endocrine Disorders: An Updated Narrative Review

mRNA vaccines against respiratory viruses

Contact Info

Product

Resources

About